Confluence Wealth Services Inc. Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Confluence Wealth Services Inc. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,288 shares of the medical research company’s stock after selling 230 shares during the quarter. Confluence Wealth Services Inc.’s holdings in Thermo Fisher Scientific were worth $1,739,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TMO. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares in the last quarter. Root Financial Partners LLC lifted its stake in Thermo Fisher Scientific by 5.0% in the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock worth $252,000 after purchasing an additional 24 shares in the last quarter. Rossmore Private Capital boosted its holdings in shares of Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after purchasing an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its holdings in shares of Thermo Fisher Scientific by 3.1% in the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after purchasing an additional 24 shares during the last quarter. Finally, ARS Wealth Advisors Group LLC lifted its position in shares of Thermo Fisher Scientific by 1.6% in the first quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company’s stock worth $778,000 after buying an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. Raymond James Financial reaffirmed an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Finally, HSBC reiterated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $585.37.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $543.88 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a market capitalization of $205.38 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. The firm’s 50-day moving average is $482.58 and its 200 day moving average is $446.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.